Study type

Study topic

Disease /health condition
Human medicinal product
Medical device

Study type

Non-interventional study

Scope of the study

Drug utilisation

Data collection methods

Primary data collection
Non-interventional study

Non-interventional study design

Cohort
Other

Non-interventional study design, other

Multicenter, open-label, non-interventional study
Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(R03AK06) salmeterol and fluticasone
salmeterol and fluticasone

Medical condition to be studied

Asthma
Population studied

Short description of the study population

Patients with confirmed diagnosis of bronchial asthma and who were being treated with Airflusal® Forspiro®.

Age groups

Adolescents (12 to < 18 years)
Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Special population of interest

Other

Special population of interest, other

Asthma patients

Estimated number of subjects

200
Study design details

Main study objective

To evaluate the impact on clinical effects, user-friendliness and patient's acceptance of Airflusal® Forspiro® in the treatment of asthma under real life conditions.

Outcomes

Primary objectives- To find out about patients' own assessment of the control of their asthma (using the ACT)- To find out about any change in patients' quality of life. Secondary objectives- To assess patients' acceptance of Airflusal® Forspiro® Inhaler- To obtain information about manipulation and user-friendliness of the new Forspiro® inhaler.

Data analysis plan

All statistical evaluations will be descriptive. No confirmatory statistical tests will be performed. Exploratory comparisons of subgroups are planned as are transverse and longitudinal comparisons. P-values of statistical tests are descriptive and do not relate to testing hypotheses.